3.4 Drug-Receptor Theory
Receptor theory provides the quantitative framework for understanding how drugs bind to receptors and produce biological effects. From Clark's occupancy theory (1933) through the operational model of Black & Leff (1983), these models underpin all of modern pharmacology.
Historical Development
Langley proposes "receptive substance" concept based on curare and nicotine experiments on frog muscle.
Ehrlich coins "receptor" and states: "Corpora non agunt nisi fixata" (substances do not act unless bound).
A.J. Clark publishes occupancy theory: response proportional to fraction of receptors occupied.
Ariens introduces intrinsic activity (alpha) to explain partial agonists.
Stephenson introduces efficacy concept: maximal response needs only fractional occupancy (spare receptors).
Schild develops quantitative analysis of competitive antagonism.
Black & Leff publish the operational model unifying agonism and antagonism in one equation.
Derivation 1: Clark's Occupancy Theory
Clark assumed that the biological response is directly proportional to the fraction of receptors occupied by the agonist. We derive this from mass-action kinetics.
Step 1: The Binding Equilibrium
A drug A binds to receptor R to form complex AR:
\( A + R \underset{k_{-1}}{\overset{k_1}{\rightleftharpoons}} AR \)
At equilibrium, the rate of association equals the rate of dissociation:
\( k_1[A][R] = k_{-1}[AR] \)
Step 2: Define the Dissociation Constant
Rearranging for the equilibrium dissociation constant K_D:
\( K_D = \frac{k_{-1}}{k_1} = \frac{[A][R]}{[AR]} \)
K_D has units of concentration (typically nM or uM). A smaller K_D means higher affinity.
Step 3: Conservation of Receptors
Total receptors R_T = free receptors + occupied receptors:
\( [R_T] = [R] + [AR] \quad \Rightarrow \quad [R] = [R_T] - [AR] \)
Step 4: Solve for Fractional Occupancy
Substituting [R] = [R_T] - [AR] into the K_D expression:
\( K_D = \frac{[A]([R_T] - [AR])}{[AR]} = \frac{[A][R_T]}{[AR]} - [A] \)
\( K_D + [A] = \frac{[A][R_T]}{[AR]} \)
\( \frac{[AR]}{[R_T]} = \frac{[A]}{K_D + [A]} \)
Clark's Occupancy Equation
Assuming response is proportional to occupancy:
\( \frac{E}{E_{max}} = \frac{[AR]}{[R_T]} = \frac{[A]}{K_D + [A]} \)
This is a rectangular hyperbola (identical in form to the Michaelis-Menten equation). When [A] = K_D, the occupancy is exactly 50%. The equation predicts that EC_50 = K_D under Clark's assumptions.
Derivation 2: Ariens' Intrinsic Activity
Clark's model could not explain why some drugs (partial agonists) produce a submaximal response even at 100% occupancy. Ariens (1954) introduced intrinsic activity (alpha) to account for this.
The Modification
Ariens multiplied Clark's occupancy equation by a proportionality constant alpha:
\( E = \alpha \cdot E_{max} \cdot \frac{[A]}{K_D + [A]} \)
where alpha (intrinsic activity) ranges from 0 to 1:
\( \alpha = 1 \)
Full agonist
Morphine, isoproterenol
\( 0 < \alpha < 1 \)
Partial agonist
Buprenorphine, pindolol
\( \alpha = 0 \)
Antagonist
Naloxone, propranolol
Limitation: Ariens' model treats alpha as a fixed drug property, but it is actually tissue-dependent. A partial agonist in one tissue may act as a full agonist in another tissue with more receptor reserve.
Derivation 3: Stephenson's Efficacy & Stimulus-Response Coupling
Stephenson (1956) realized that drugs differ not only in affinity but also in their ability to activate receptors once bound. He introduced "efficacy" (e) as a property of the drug-receptor complex and separated the stimulus from the response.
Step 1: Define the Stimulus
The stimulus S is the product of drug efficacy (e) and fractional occupancy:
\( S = e \cdot \frac{[AR]}{[R_T]} = e \cdot \frac{[A]}{K_D + [A]} \)
Here, e is intrinsic to the drug-receptor pair (not the tissue).
Step 2: The Response Function
The response E is a nonlinear function of the stimulus, determined by tissue-specific amplification:
\( E = f(S) = f\left( e \cdot \frac{[AR]}{[R_T]} \right) \)
The function f is typically hyperbolic and accounts for signal amplification cascades in the tissue.
Step 3: Spare Receptors Explained
If e is large, a small fractional occupancy produces a large stimulus. The tissue amplification function f(S) saturates before all receptors are occupied, meaning:
\( EC_{50} \ll K_D \)
The "spare" or "reserve" receptors are those not needed for maximal response. This concept explains why irreversible antagonists (e.g., phenoxybenzamine) initially shift the dose-response curve rightward without reducing E_max.
Key insight: Stephenson separated binding (affinity, K_D) from activation (efficacy, e). Two drugs with identical K_D can produce very different responses depending on their efficacy values.
Derivation 4: The Operational Model (Black & Leff, 1983)
The operational model provides a unified, quantitative framework that connects receptor binding directly to tissue response through a transducer ratio tau.
Step 1: Receptor Binding
From mass-action, the concentration of occupied receptors [AR] follows:
\( [AR] = \frac{[R_T][A]}{K_A + [A]} \)
where K_A is the equilibrium dissociation constant for the agonist-receptor complex.
Step 2: Transducer Function
The tissue converts occupied receptors into response via a hyperbolic transducer function:
\( E = \frac{E_{max} \cdot [AR]^n}{[AR]^n + K_E^n} \)
where K_E is the [AR] that produces 50% of E_max, and n is the transducer slope (Hill coefficient of the stimulus-response coupling).
Step 3: Define the Transducer Ratio tau
Define tau = [R_T]/K_E, the ratio of total receptors to the transducer constant. This captures both receptor density and coupling efficiency:
\( \tau = \frac{[R_T]}{K_E} \)
Step 4: Substitute and Simplify
Substituting [AR] = [R_T][A]/(K_A + [A]) and K_E = [R_T]/tau into the transducer function:
\( E = \frac{E_{max} \left( \frac{[R_T][A]}{K_A + [A]} \right)^n}{\left( \frac{[R_T][A]}{K_A + [A]} \right)^n + \left( \frac{[R_T]}{\tau} \right)^n} \)
Dividing numerator and denominator by [R_T]^n:
\( E = \frac{E_{max} \left( \frac{[A]}{K_A + [A]} \right)^n}{\left( \frac{[A]}{K_A + [A]} \right)^n + \frac{1}{\tau^n}} \)
Multiplying top and bottom by tau^n (K_A + [A])^n:
The Operational Model Equation
\( E = \frac{E_{max} \cdot \tau^n \cdot [A]^n}{[A]^n(1 + \tau^n) + K_A^n} \)
When tau is large (high efficacy/receptor reserve): the drug behaves as a full agonist, EC_50 approaches K_A/(1+tau) which is much less than K_A. When tau is small (low efficacy): the drug behaves as a partial agonist, E_max_obs = E_max * tau^n/(1+tau^n) which is less than E_max.
Derivation 5: Schild Analysis for Competitive Antagonists
Schild analysis quantifies the potency of competitive antagonists and confirms their mechanism of action.
Step 1: Competitive Antagonism Setup
With a competitive antagonist B present, the agonist A must compete for the same binding site. The fraction of receptors occupied by A in the presence of B:
\( \frac{[AR]}{[R_T]} = \frac{[A]}{[A] + K_A\left(1 + \frac{[B]}{K_B}\right)} \)
where K_B is the dissociation constant of the antagonist.
Step 2: Define the Dose Ratio
To achieve the same response (same occupancy) in the presence of B, the agonist concentration must increase. Let [A'] be the new EC_50. The dose ratio DR is:
\( DR = \frac{[A']}{[A]} \)
For equal occupancy, the apparent K_A becomes K_A(1 + [B]/K_B), so:
\( DR = 1 + \frac{[B]}{K_B} \)
Step 3: The Schild Plot
Taking logarithms of both sides of DR - 1 = [B]/K_B:
\( \log(DR - 1) = \log[B] - \log K_B \)
A plot of log(DR - 1) vs log[B] yields a straight line with slope = 1 and x-intercept = log(K_B). The x-intercept is the pA_2 value, a key pharmacological parameter.
Schild Equation
\( \log(DR - 1) = \log[B] - \log K_B \)
A slope of exactly 1 on the Schild plot confirms competitive (surmountable) antagonism. Deviation from slope = 1 suggests non-competitive or more complex mechanisms. pA_2 = -log(K_B) is the concentration of antagonist that produces a 2-fold rightward shift.
Dose-Response Curves: Agonists & Antagonist Shift
Full Agonist
Reaches 100% E_max
Partial Agonist
Reduced E_max plateau
+ Competitive Antag.
Rightward shift, same E_max
Python Simulation: Receptor Theory Models
Receptor Theory — Clark, Ariens, Operational Model & Schild Analysis
PythonClick Run to execute the Python code
Code will be executed with Python 3 on the server
Clinical Applications
Buprenorphine in Opioid Use Disorder
A partial mu-opioid agonist (low tau). At therapeutic doses, it provides enough activation to prevent withdrawal but its ceiling effect limits respiratory depression. Demonstrates Stephenson's efficacy concept: lower e than morphine at the same receptor.
Beta-Blockers & Schild Analysis
Propranolol is a competitive antagonist at beta-adrenergic receptors. Schild analysis confirms pA_2 approximately 8.5 (K_B approximately 3 nM). The dose-response curve to isoproterenol shifts rightward in parallel with no reduction in E_max.
Spare Receptors in Insulin Signaling
Adipocytes have large receptor reserves for insulin. Maximal glucose uptake occurs at only 5-10% receptor occupancy (EC_50 is much less than K_D). This is why partial receptor loss in type 2 diabetes initially preserves normal glucose handling.
Operational Model in Drug Discovery
The tau parameter from the operational model allows comparison of agonist efficacy across tissues. High-throughput screening uses tau to rank-order lead compounds independently of receptor expression levels in the assay system.
Summary of Receptor Theory Models
| Model | Key Equation | Key Parameter | Limitation |
|---|---|---|---|
| Clark (1933) | \( E/E_{max} = [A]/(K_D + [A]) \) | K_D | Cannot explain partial agonists |
| Ariens (1954) | \( E = \alpha E_{max} [A]/(K_D + [A]) \) | alpha (0-1) | alpha is tissue-dependent |
| Stephenson (1956) | \( E = f(e \cdot [AR]/[R_T]) \) | Efficacy e | f() not specified |
| Black & Leff (1983) | \( E = E_{max}\tau^n[A]^n/([A]^n(1+\tau^n)+K_A^n) \) | tau, K_A | Assumes hyperbolic transduction |
| Schild (1959) | \( \log(DR-1) = \log[B] - \log K_B \) | pA_2, K_B | Competitive antagonists only |
Key Takeaways
- 1.
Clark's occupancy theory established that response follows a hyperbolic function of drug concentration, with K_D as the sole determinant.
- 2.
Ariens' intrinsic activity alpha introduced the concept that drugs have different maximal capacities to activate receptors.
- 3.
Stephenson's separation of stimulus and response explains spare receptors and tissue-dependent drug behavior.
- 4.
The operational model's tau parameter unifies affinity and efficacy into a single quantitative framework used in modern drug discovery.
- 5.
Schild analysis provides a rigorous method to classify antagonist mechanism and quantify antagonist potency (pA_2).
Practice Problems
Problem 1: EC$_{50}$ from Dose-Response DataAn agonist produces responses of 10%, 30%, 52%, 78%, and 95% of $E_{\max}$ at concentrations of 1, 3, 10, 30, and 100 nM. Estimate the EC$_{50}$ using the Hill equation.
Solution:
1. The Hill equation for the dose-response relationship is:
2. At 50% response, $[A] = EC_{50}$. From the data, 52% response occurs at 10 nM, so our initial estimate is $EC_{50} \approx 10$ nM.
3. To estimate the Hill coefficient, use the relationship at two points. Rearranging: $\log\!\left(\frac{E/E_{\max}}{1 - E/E_{\max}}\right) = n_H \log[A] - n_H \log EC_{50}$.
4. Using the 3 nM and 30 nM data points:
5. With $n_H \approx 1$ (consistent with a single binding site), the dose-response follows a simple rectangular hyperbola:
A Hill coefficient near 1 indicates non-cooperative binding, as expected for a simple drug-receptor interaction without allosteric effects.
Problem 2: Schild Plot AnalysisA competitive antagonist shifts the agonist dose-response curve rightward. The dose ratios (DR) at antagonist concentrations of 1, 10, and 100 nM are 2.0, 11.0, and 101. Construct a Schild plot and determine the pA$_2$ and Schild slope.
Solution:
1. The Schild equation for competitive antagonism is:
2. Taking logarithms: $\log(DR - 1) = \log[B] - \log K_B$. Compute $\log(DR-1)$ vs $\log[B]$:
3. The Schild slope is:
4. A slope of exactly 1.0 confirms competitive antagonism. The x-intercept (where $\log(DR-1) = 0$) gives $\log K_B$:
5. The pA$_2$ is:
A pA$_2$ of 9.0 indicates a highly potent antagonist. The unit slope confirms that the antagonism is purely competitive and surmountable.
Problem 3: Operational Model $\tau$ ParameterIn Black & Leff's operational model, an agonist has $K_A = 100$ nM and produces $E_{\max} = 80\%$ of the system maximum. If the transducer function is $E = E_m\tau[A]/(K_A + [A](1+\tau))$, calculate $\tau$ and the operational efficacy.
Solution:
1. In the operational model, when $n = 1$, the maximum agonist response (at $[A] \to \infty$) is:
2. Given $E_{\max}/E_m = 0.80$, solve for $\tau$:
3. Therefore:
4. The observed EC$_{50}$ in the operational model is:
5. The ratio $K_A/EC_{50} = 5$ indicates a 5-fold receptor reserve (spare receptors). The drug needs to occupy only 20% of receptors to achieve a half-maximal response, because $\tau = 4$ provides sufficient stimulus amplification through the signal transduction cascade.
Problem 4: Intrinsic Activity from $E_{\max}$Three drugs acting at the same receptor produce maximal responses of 100%, 60%, and 25% of the tissue maximum. Classify each drug and calculate Ariens' intrinsic activity $\alpha$ for each.
Solution:
1. Ariens' intrinsic activity is defined as the ratio of the drug's maximal response to the tissue maximum response:
2. For Drug A ($E_{\max} = 100\%$):
3. For Drug B ($E_{\max} = 60\%$):
4. For Drug C ($E_{\max} = 25\%$):
5. Classification summary:
Note that $\alpha$ is tissue-dependent: a drug with $\alpha = 0.6$ in one tissue may be a full agonist in a tissue with greater receptor reserve. Stephenson's efficacy $e$ is the system-independent measure. The operational model's $\tau$ unifies both perspectives.
Problem 5: Receptor Reserve and Irreversible AntagonismAn agonist with $K_A = 50$ nM has EC$_{50} = 10$ nM in a tissue. After irreversible antagonist treatment that eliminates 60% of receptors, what happens to $E_{\max}$ and EC$_{50}$? Assume the operational model with $n = 1$.
Solution:
1. First find the original $\tau$. From $EC_{50} = K_A/(1+\tau)$:
2. Since $\tau = e[R_T]/K_E$ and $\tau \propto [R_T]$, reducing receptor number by 60% gives:
3. The new $E_{\max}$ (as fraction of system maximum) is:
4. The new EC$_{50}$ is:
5. Summary of the irreversible antagonist effect:
The original $E_{\max} = \tau/(1+\tau) = 80\%$. Unlike competitive antagonism (which only right-shifts the curve), irreversible antagonism both reduces $E_{\max}$ and increases EC$_{50}$. The 5-fold receptor reserve ($K_A/EC_{50} = 5$) provides a buffer: even after losing 60% of receptors, the drug still achieves 61.5% of system maximum.